Nutritional and health experts say that having it to start the day has major benefits including blood sugar levels, ...

Stroke was the fourth leading cause of death in the U.S. in 2023, according to the Centers for Disease Control and Prevention ...

The pharmaceutical giant presented mid-stage trial data on the pill, muvalaplin, at the American Heart Association Scientific ...

Melbourne researchers are helping expand options for people with high cholesterol that puts them at risk of heart attack or stroke, including world-first drugs for potentially deadly conditions.

Data reveal a strong association between non–high-density lipoprotein (non-HDL) cholesterol to HDL cholesterol ratio and ...

Excess cholesterol is known to form artery-clogging plaques that can lead to stroke, arterial disease, heart attack, and more, making it the focus of many heart health campaigns.

Lilly’s muvalaplin is the first oral drug to show positive Phase II findings for Lp(a) reduction, eliciting up to an 86% drop ...

Since the discovery of statins and the Scandinavian Simvastatin Survival Study (4S) results three decades ago, remarkable advances have been made in the treatment of dyslipidaemia, a major risk factor ...

Lilly's drug is the only oral treatment in a field of several injectable therapies being tested to treat high Lp(a), a risk factor for heart disease that affects one in five individuals globally ...

Dietary niacin intake reduces risks of all-cause and cardiovascular mortality in US adults, with benefits more pronounced in non-diabetic individuals and linked to NAD metabolism improvements.

Inflammation is generally the indication of a health problem. But new research suggests we think differently about inflammation, especially in relation to heart disease and the prevention of atheroscl ...

Lp (a) is a genetically driven variant of low-density lipoprotein (LDL) cholesterol, that is known to be an independent risk ...